For laboratory research use only. Not for human or veterinary use.Lab research use only. Not for human or animal use.
Peptides studied in metabolic research contexts — including the incretin analogues retatrutide and semaglutide — supplied to laboratories and researchers for in vitro laboratory use. Every vial is independently lab-tested before release, with published certificates listed by product and strength in the COA library, stocked in Australia and dispatched the same business day when ordered before 12pm Sydney time. For in vitro research purposes only.
Metabolic research peptides are compounds studied in metabolic and endocrine laboratory research. This category holds retatrutide, which is described as acting at the GIP, GLP-1 and glucagon receptors at once; semaglutide, a single-receptor GLP-1 agonist; and cagrilintide, a 37-amino-acid amylin analogue. All three arrive as freeze-dried powder in sealed glass vials, listed by Australian Research Peptides for in vitro laboratory research.
Retatrutide vials hold 10 mg, 20 mg or 30 mg of HPLC-tested freeze-dried powder, sealed in glass and shipped to every state and territory. The single synthetic chain, built on a GIP backbone, carries a C20 fatty di-acid that binds albumin. In laboratory assays it binds the GIP, GLP-1 and glucagon receptors together, and it is studied in metabolic research. In vitro research purposes only.
It is in stock, and orders paid before 12pm Sydney time on a business day are posted the same day. Studied in metabolic research, Semaglutide is a laboratory-made copy of GLP-1, a hormone released by the gut, with two of its 31 amino acids swapped and a fatty chain attached so it lasts longer. In vitro research purposes only.
Cagrilintide is a 37-amino-acid analogue of amylin, a hormone made in the pancreas. Its chain differs from human amylin at six places, and a twenty-carbon fatty chain joins the front end. Registries file it under PubChem CID 171397054 and UNII AO43BIF1U8. A reference material for glassware and cell-culture work, it is tested by an independent laboratory the manufacturer commissions. In vitro research purposes only.
Retatrutide — often shortened to reta — is bought in Australia from Australian Research Peptides and shipped domestically: weekday orders completed before 12pm Sydney time are dispatched from Sydney the same business day, so an order reaches laboratories and researchers in days without crossing a border or waiting on customs. It is listed on this page in three vial strengths of HPLC-tested freeze-dried powder, with certificates published by product and strength in the COA library. Supplied for in vitro laboratory research only.
Choose by which receptor family the published work sits in. Retatrutide is classed as a triple agonist, reported at the GIP, GLP-1 and glucagon receptors together, and is listed in three vial strengths. Semaglutide is classed as single-target at the GLP-1 receptor, and cagrilintide is an amylin analogue; each is listed in a single 10 mg vial.
| Compound | Vial strengths listed | Studied in relation to |
|---|---|---|
| Retatrutide | 10 mg, 20 mg, 30 mg | metabolic research |
| Semaglutide | 10 mg | GLP-1 receptor research |
| Cagrilintide | 10 mg | amylin receptor research |